Literature DB >> 10861010

T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

J Kipnis1, E Yoles, Z Porat, A Cohen, F Mor, M Sela, I R Cohen, M Schwartz.   

Abstract

We recently reported that the posttraumatic spread of degeneration in the damaged optic nerve can be attenuated by the adoptive transfer of autoimmune T cells specific to myelin basic protein. However, it would be desirable to obtain immune neuroprotection free of any possible autoimmune disease. In an attempt to obtain disease-free immune neuroprotection, we used the synthetic four-amino acid polymer copolymer 1 (Cop-1), which is known not to be encephalitogenic despite its cross-reactivity with myelin basic protein. We show here that active immunization with Cop-1 administered in adjuvant, as well as adoptive transfer of T cells reactive to Cop-1, can inhibit the progression of secondary degeneration after crush injury of the rat optic nerve. These results have implications for the treatment of optic neuropathies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861010      PMCID: PMC16565          DOI: 10.1073/pnas.97.13.7446

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Autoimmune T cells as potential neuroprotective therapy for spinal cord injury.

Authors:  E Hauben; U Nevo; E Yoles; G Moalem; E Agranov; F Mor; S Akselrod; M Neeman; I R Cohen; M Schwartz
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

2.  T-lymphocyte entry into the central nervous system.

Authors:  W F Hickey; B L Hsu; H Kimura
Journal:  J Neurosci Res       Date:  1991-02       Impact factor: 4.164

Review 3.  Oral tolerance for the treatment of autoimmune diseases.

Authors:  H L Weiner
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

Review 4.  Diagnosis and pathogenesis of glaucomatous optic neuropathy: morphological aspects.

Authors:  J B Jonas; W M Budde
Journal:  Prog Retin Eye Res       Date:  2000-01       Impact factor: 21.198

5.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

6.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

7.  Binding of random copolymers of three amino acids to class II MHC molecules.

Authors:  M Fridkis-Hareli; R Aharoni; D Teitelbaum; R Arnon; M Sela; J L Strominger
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

Review 8.  Potential neuroprotective therapy for glaucomatous optic neuropathy.

Authors:  E Yoles; M Schwartz
Journal:  Surv Ophthalmol       Date:  1998 Jan-Feb       Impact factor: 6.048

Review 9.  Neuroprotection: a new treatment modality for glaucoma?

Authors:  M Schwartz; E Yoles
Journal:  Curr Opin Ophthalmol       Date:  2000-04       Impact factor: 3.761

10.  A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes.

Authors:  T Hünig; H J Wallny; J K Hartley; A Lawetzky; G Tiefenthaler
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  71 in total

Review 1.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Abstracts of the 13th Meeting of the European Neurological Society. 14-18 June 2003, Istanbul, Turkey.

Authors: 
Journal:  J Neurol       Date:  2003-05       Impact factor: 4.849

Review 3.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 4.  Rett syndrome and other autism spectrum disorders--brain diseases of immune malfunction?

Authors:  N C Derecki; E Privman; J Kipnis
Journal:  Mol Psychiatry       Date:  2010-02-23       Impact factor: 15.992

5.  Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.

Authors:  Alexander M Herrmann; Kerstin Göbel; Ole J Simon; Nico Melzer; Michael K Schuhmann; Max-Philipp Stenner; Andreas Weishaupt; Christoph Kleinschnitz; Stefan Bittner; Patrick Meuth; Olaf Stuve; Thomas Budde; Bernd C Kieseier; Heinz Wiendl; Sven G Meuth
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 6.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

7.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 8.  Neuroprotection in glaucoma: drug-based approaches.

Authors:  William Cheung; Li Guo; M Francesca Cordeiro
Journal:  Optom Vis Sci       Date:  2008-06       Impact factor: 1.973

9.  The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

Authors:  Rina Aharoni; Raya Eilam; Hagit Domev; Galya Labunskay; Michael Sela; Ruth Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

10.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.